MedTrace Logo

Ranolazine Cardioprotection in PCI

NCT01767987 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2017-09-14

Study results available
· View outcomes & findings →

Summary

The investigators will test if upfront dosing of Ranolazine can reduce myocardial biomarker release (CK-MB, Troponin) post percutaneous coronary intervention (PCI).

Conditions

  • Acute Coronary Syndrome

Interventions

DRUG

Ranolazine

Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI

DRUG

Placebo

Drug: Placebo Oral dose twice per day for 3 days leading up to PCI

Sponsors & Collaborators

Principal Investigators

  • Harvey S Hahn, MD · Kettering Health Network

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01767987 on ClinicalTrials.gov